by Peggy Baker | Apr 8, 2021 | Clinical, News, Research
The CGRP Monoclonal Antibodies for Migraine Are a Prime Example Lawrence Robbins, M.D. This letter is in response to an excellent July, 2020 article “Migraine and CGRP Monoclonal Antibodies: A Review of Cardiovascular Side Effects and Safety Profile” (Boldig and...
by Peggy Baker | Jan 9, 2021 | Clinical
Bert Ray, MD Laser therapy has been utilized for multiple medical problems, as the light energy improves mitochondrial function in cells that are involved with medical illnesses, has an anti-inflammatory effect, boosts the immune response, and restores oxidative redox...
by Peggy Baker | Oct 12, 2020 | Clinical, News, Research
Lawrence Robbins, MD INTRODUCTION Migraine often results in disability and diminished quality of life. Despite this, our species remains particularly vulnerable to migraine. Why is this so? Evolution may provide answers. The study of evolution and disease is not...
by Peggy Baker | Jan 12, 2020 | Clinical, News, Research
Lawrence Robbins,M.D. Gepants are small molecule calcitonin gene-related peptide (CGRP) receptor antagonists. The preventive CGRP monoclonal antibodies(Aimovig, Emgality, Ajovy) are large molecules, delivered once per month as a SQ injection. Seven gepants have been...
by Peggy Baker | Jan 12, 2020 | Clinical, News, Policy
Lisa Edgerton, PharmD, BCPS, CPP, Olivia Herndon, MA, and Joseph Pino, MD, MHA Wilmington is a community in southeastern North Carolina known for its beautiful beaches, historic river-walk district, and the largest domestic television and movie production facility...
by Peggy Baker | Oct 21, 2019 | Clinical, Policy, Research
James N. Weisberg, PhD This article is adapted from a chapter in a soon to be published text: Weisberg, J.N., Paul, C. & Twyner, C. Personality and Personality Disorders in Chronic Pain. In Incayawar, M., Clark, M. & Maldonado-Bouchard, S. (Eds.). Overlapping...
